{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:44:56Z","timestamp":1791474296420,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Menarini International Operations Luxembourg SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12325-020-01455-2","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T11:02:35Z","timestamp":1596884555000},"page":"4068-4085","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Angiotensin-Converting Enzyme Inhibition: Beyond Blood Pressure Control\u2014The Role of Zofenopril"],"prefix":"10.1007","volume":"37","author":[{"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Omboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,8]]},"reference":[{"issue":"1","key":"1455_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11892-006-0045-4","volume":"6","author":"K Kalantarinia","year":"2006","unstructured":"Kalantarinia K, Okusa MD. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. Curr Diab Rep. 2006;6(1):8\u201316.","journal-title":"Curr Diab Rep."},{"issue":"12","key":"1455_CR2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1463-1326.2008.00898.x","volume":"10","author":"H Abuissa","year":"2008","unstructured":"Abuissa H, O\u2019Keefe J Jr. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes Obes Metab. 2008;10(12):1157\u201366.","journal-title":"Diabetes Obes Metab"},{"key":"1455_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/heartjnl-2017-312121","volume":"103","author":"CM Otto","year":"2017","unstructured":"Otto CM. Heartbeat: renin-angiotensin system blockade for prevention of cardiovascular disease. Heart. 2017;103:1305\u20137.","journal-title":"Heart"},{"key":"1455_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18553\/jmcp.2007.13.s8-b.9","volume":"13","author":"S Atlas","year":"2007","unstructured":"Atlas S. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13:9\u201320.","journal-title":"J Manag Care Pharm."},{"key":"1455_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1210\/er.2003-0001","volume":"24","author":"RM Carey","year":"2003","unstructured":"Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24:261\u20137.","journal-title":"Endocr Rev"},{"issue":"10","key":"1455_CR6","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/circresaha.120.317015","volume":"126","author":"M Gheblawi","year":"2020","unstructured":"Gheblawi M, Wang K, Viveiros A, et al. Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Circ Res. 2020;126(10):1456\u201374.","journal-title":"Circ Res."},{"key":"1455_CR7","unstructured":"Magellan. Angiotensin modulators: ACE inhibitors and direct renin inhibitors review. Cincinnati: Provider Synergies, LLC; 2012. p. 1\u201328."},{"issue":"7","key":"1455_CR8","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/S0735-1097(01)01229-3","volume":"37","author":"ME Khalil","year":"2001","unstructured":"Khalil ME, Basher AW, Brown EJ Jr, Alhaddad IA. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol. 2001;37(7):1757\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"Pt A","key":"1455_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.phrs.2017.05.020","volume":"125","author":"CM Ferrario","year":"2017","unstructured":"Ferrario CM, Mullick AE. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res. 2017;125(Pt A):57\u201371.","journal-title":"Pharmacol Res"},{"issue":"10","key":"1455_CR10","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. Authors\/Task Force Members: 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953\u20132041.","journal-title":"J Hypertens"},{"key":"1455_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/978-3-642-18497-0_17","volume-title":"Angiotensin","author":"P Gohlke","year":"2004","unstructured":"Gohlke P, Scholkens BA. ACE inhibitors: pharmacology. In: Unger T, Scholkens BA, editors. Angiotensin. Berlin: Springer; 2004. p. 375\u2013413."},{"issue":"1","key":"1455_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2165\/00003495-199754010-00012","volume":"54","author":"R Davis","year":"1997","unstructured":"Davis R, Coukell A, McTavish D. Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure. Drugs. 1997;54(1):103\u201316.","journal-title":"Drugs."},{"key":"1455_CR13","first-page":"CD003823","volume":"4","author":"BS Heran","year":"2008","unstructured":"Heran BS, Wong MMY, Heran IK, Wright J. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008;4:CD003823.","journal-title":"Cochrane Database Syst Rev."},{"key":"1455_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1001\/jama.1997.03550030052033","volume":"278","author":"JB Kostis","year":"1997","unstructured":"Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212\u20136.","journal-title":"JAMA"},{"issue":"27","key":"1455_CR15","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J."},{"key":"1455_CR16","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","volume":"355","author":"MD Flather","year":"2000","unstructured":"Flather MD, Yusuf S, K\u00f8ber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575\u201381.","journal-title":"Lancet"},{"issue":"8","key":"1455_CR17","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jacc.2005.11.073","volume":"47","author":"MH Al-Mallah","year":"2006","unstructured":"Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2006;47(8):1576\u201383.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1455_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407\u201377.","journal-title":"Eur Heart J"},{"key":"1455_CR19","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1161\/01.CIR.97.22.2192","volume":"97","author":"M Pfeffer","year":"1998","unstructured":"Pfeffer M. ACE inhibitors in acute myocardial infarction patient selection and timing. Circulation. 1998;97:2192\u20134.","journal-title":"Circulation"},{"key":"1455_CR20","doi-asserted-by":"crossref","unstructured":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998;97(22):2202\u201312.","DOI":"10.1161\/01.CIR.97.22.2202"},{"issue":"2","key":"1455_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1365-2125.2007.02991.x","volume":"65","author":"ML Hansen","year":"2008","unstructured":"Hansen ML, Gislason GH, K\u00f8ber L, et al. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol. 2008;65(2):217\u201323.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1455_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","journal-title":"Eur Heart J."},{"key":"1455_CR23","doi-asserted-by":"publisher","first-page":"f6008","DOI":"10.1136\/bmj.f6008","volume":"347","author":"HY Wu","year":"2013","unstructured":"Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. Version 2. BMJ. 2013;347:f6008.","journal-title":"BMJ"},{"issue":"Suppl 1","key":"1455_CR24","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1681\/ASN.2004110968","volume":"16","author":"C Chiurchiu","year":"2005","unstructured":"Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol. 2005;16(Suppl 1):S58\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"1455_CR25","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00005344-198906000-00011","volume":"13","author":"JM DeForrest","year":"1989","unstructured":"DeForrest JM, Waldron TL, Krapcho J, et al. Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. J Cardiovasc Pharmacol. 1989;13:887\u201394.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1455_CR26","doi-asserted-by":"publisher","first-page":"D101","DOI":"10.1016\/0002-9149(91)90266-N","volume":"68","author":"E Ambrosioni","year":"1991","unstructured":"Ambrosioni E, Borghi C, Magnani B. Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. SMILE pilot study working party. Am J Cardiol. 1991;68:D101\u201310.","journal-title":"Am J Cardiol."},{"key":"1455_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1056\/NEJM199501123320203","volume":"332","author":"E Ambrosioni","year":"1995","unstructured":"Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332:80\u20135.","journal-title":"N Engl J Med"},{"key":"1455_CR28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0895-7061(99)00042-4","volume":"12","author":"C Borghi","year":"1999","unstructured":"Borghi C, Bacchelli S, Degli Esposti D, Bignamini A, Magnani B, Ambrosioni E. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of myocardial infarction long-term evaluation. Am J Hypertens. 1999;12:665\u201372.","journal-title":"Am J Hypertens"},{"key":"1455_CR29","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.2337\/diacare.26.6.1862","volume":"26","author":"C Borghi","year":"2003","unstructured":"Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E, SMILE Study. Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care. 2003;26:1862\u20138.","journal-title":"Diabetes Care"},{"key":"1455_CR30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1472-8206.2009.00704.x","volume":"23","author":"C Borghi","year":"2009","unstructured":"Borghi C, Cicero AF, Bacchelli S, Degli Esposti D, Ambrosioni E, Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study. Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial. Fundam Clin Pharmacol. 2009;23:641\u20138.","journal-title":"Fundam Clin Pharmacol"},{"key":"1455_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2147\/VHRM.S2799","volume":"4","author":"C Borghi","year":"2008","unstructured":"Borghi C, Cicero AF, Ambrosioni E. Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vasc Health Risk Manag. 2008;4:665\u201371.","journal-title":"Vasc Health Risk Manag"},{"key":"1455_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ahj.2006.02.022","volume":"152","author":"C Borghi","year":"2006","unstructured":"Borghi C, Bacchelli S, Degli ED, Ambrosioni E. Survival of Myocardial Infarction Long-Term Evaluation Study. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction. Am Heart J. 2006;152:470\u20137.","journal-title":"Am Heart J."},{"key":"1455_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1067\/mhj.2003.24","volume":"145","author":"C Borghi","year":"2003","unstructured":"Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J. 2003;145:80\u20137.","journal-title":"Am Heart J."},{"issue":"7","key":"1455_CR34","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/clc.22017","volume":"35","author":"C Borghi","year":"2012","unstructured":"Borghi C, Ambrosioni E, Novo S, Vinereanu D, Ambrosio G. SMILE-4 Working Party. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol. 2012;35(7):416\u201323.","journal-title":"Clin Cardiol."},{"issue":"5","key":"1455_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/FJC.0000000000000473","volume":"69","author":"C Borghi","year":"2017","unstructured":"Borghi C, Omboni S, Novo S, Vinereanu D, Ambrosio G, Ambrosioni E. Early treatment with zofenopril and ramipril in combination with acetyl salicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a 5-year follow-up of patients of the SMILE-4 Study. J Cardiovasc Pharmacol. 2017;69(5):298\u2013304.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"1455_CR36","doi-asserted-by":"publisher","first-page":"147032031665648","DOI":"10.1177\/1470320316656480","volume":"17","author":"C Borghi","year":"2016","unstructured":"Borghi C, Omboni S, Novo S, Vinereanu D, Ambrosio G, Ambrosioni E, SMILE-4 Working Party. Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study. J Renin Angiotensin Aldosterone Syst. 2016;17(4):1470320316656480.","journal-title":"J Renin Angiotensin Aldosterone Syst."},{"key":"1455_CR37","doi-asserted-by":"publisher","first-page":"445.e7","DOI":"10.1016\/j.ahj.2006.12.005","volume":"153","author":"C Borghi","year":"2007","unstructured":"Borghi C, Ambrosioni E, Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)\u2014ISCHEMIA study. Am Heart J. 2007;153:445.e7\u201314.","journal-title":"Am Heart J."},{"issue":"1","key":"1455_CR38","doi-asserted-by":"publisher","first-page":"e000195","DOI":"10.1136\/openhrt-2014-000195","volume":"2","author":"C Borghi","year":"2015","unstructured":"Borghi C, Omboni S, Cicero AF, et al. Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a post hoc analysis of the SMILE-4 Study in patients according to levels of left ventricular ejection fraction at entry. Open Heart. 2015;2(1):e000195.","journal-title":"Open Heart."},{"issue":"1","key":"1455_CR39","doi-asserted-by":"publisher","first-page":"e000220","DOI":"10.1136\/openhrt-2014-000220","volume":"2","author":"C Borghi","year":"2015","unstructured":"Borghi C, Omboni S, Reggiardo G, Bacchelli S, Degli Esposti D, Ambrosioni E. Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. Open Heart. 2015;2(1):e000220.","journal-title":"Open Heart."},{"issue":"7","key":"1455_CR40","doi-asserted-by":"publisher","first-page":"e003531","DOI":"10.1161\/JAHA.116.003531","volume":"5","author":"E Donnarumma","year":"2016","unstructured":"Donnarumma E, Ali MJ, Rushing AM, et al. Zofenopril protects against myocardial ischemia-reperfusion injury by increasing nitric oxide and hydrogen sulfide bioavailability. J Am Heart Assoc. 2016;5(7):e003531.","journal-title":"J Am Heart Assoc."},{"issue":"4","key":"1455_CR41","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/ajh\/2.4.294","volume":"2","author":"DW Cushman","year":"1989","unstructured":"Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens. 1989;2(4):294\u2013306.","journal-title":"Am J Hypertens"},{"key":"1455_CR42","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2147\/TCRM.S25976","volume":"7","author":"S Omboni","year":"2011","unstructured":"Omboni S, Borghi C. Zofenopril and incidence of cough: a review of published and unpublished data. Ther Clin Risk Manag. 2011;7:459\u201371.","journal-title":"Ther Clin Risk Manag"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01455-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01455-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01455-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T14:15:51Z","timestamp":1723385751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01455-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,8]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1455"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01455-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,8]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}